title: Effect of mineral trioxide aggregate cements on transforming growth factor beta1 and bone morphogenetic protein production by human fibroblasts in vitro.
abstract: The aim of this study was to evaluate and compare the effects of two commercial mineral trioxide aggregate (MTA) cements (ProRoot MTA and MTA Angelus) on transforming growth factor (TGF)-beta1 and bone morphogenetic protein (BMP)-2 levels produced by cultured human gingival fibroblasts (HGFs). Human gingival tissues were obtained from individuals with healthy periodontium. HGFs were grown at 37 degrees C in humidified atmosphere of 5% CO(2) in Dulbecco's modified Eagle's medium, supplemented with 10% fetal calf serum, penicillin, and streptomycin. After 24 and 72 hours of exposure to the MTA products, HGF viability was determined by using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide assay. TGF-beta1 and BMP-2 levels in cell-free culture media were determined by enzyme-linked immunosorbent assay. Cell viability of the test groups was significantly lower than that of control at 24 and 72 hours (p < 0.05) but showed an increase at 72 hours (p < 0.05). Both test groups showed increased TGF beta-1 levels at 72 hours (p < 0.05), whereas the MTA Angelus group displayed higher TGF beta-1 levels than control and ProRoot MTA groups at 24 and 72 hours (p < 0.05). At 24 hours, BMP-2 levels of the ProRoot group were significantly higher than that of MTA Angelus (p < 0.05). Both test materials increased the BMP-2 levels within time (p < 0.05) and displayed similar levels at 72 hours (p > 0.05). These results suggest that both MTA products are capable of stimulating HGF to produce BMP-2, whereas the stimulatory effect for TGF beta-1 is material dependent.
authors: Department of Pediatric Dentistry, Center of Dental Sciences, Gulhane Medical Academy, Etlik, Ankara, Turkey. gunseliguven@yahoo.com
authors: Gunseli
authors: G
authors: Guven
authors: Zafer C
authors: ZC
authors: Cehreli
authors: Ali
authors: A
authors: Ural
authors: Muhittin A
authors: MA
authors: Serdar
authors: Feridun
authors: F
authors: Basak
mesh_terms: D017607:Aluminum Compounds / Q000494:pharmacology*; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000032:analysis / Q000187:drug effects*; D017610:Calcium Compounds / Q000494:pharmacology*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D004396:Coloring Agents; D004338:Drug Combinations; D005347:Fibroblasts / Q000187:drug effects*; D005881:Gingiva / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D008422:Materials Testing; D010087:Oxides / Q000494:pharmacology*; D012387:Root Canal Filling Materials / Q000494:pharmacology*; D017640:Silicates / Q000494:pharmacology*; D013778:Tetrazolium Salts; D013844:Thiazoles; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000032:analysis / Q000187:drug effects*; D053773:Transforming Growth Factor beta1 / Q000032:analysis / Q000187:drug effects*
chemical_list: D017607:Aluminum Compounds; C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D017610:Calcium Compounds; D004396:Coloring Agents; D004338:Drug Combinations; D010087:Oxides; D012387:Root Canal Filling Materials; D017640:Silicates; D013778:Tetrazolium Salts; D013844:Thiazoles; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; C086631:mineral trioxide aggregate; C022616:thiazolyl blue